drugset / Trial / NCT01791491
Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate how well adolescent kidney transplant patients tolerate a single dose of belatacept they receive at least 6 months after transplant surgery, and how their body handles the drug.
Timeline
- Start
- 2013-05-09
- Primary completion
- 2016-12-06
- Completion
- 2016-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belatacept | Protein / enzyme biologic | 7.5 mg/kg | Intravenous |
Indications
No indication recorded.